Hong Kong Patent Grant Sends BioAffinity Shares Up 50%
BIAF sits 87% above its 52-week low of $4.56 on elevated volume (8.4× avg).
Summary
BioAffinity Technologies received a Hong Kong patent for its CyPath Lung diagnostic, extending IP protection to a region with ~1.6 million annual lung cancer cases. The stock surged 50.47% to $8.05 on the news, with warrants up nearly 20%. This follows a 2025 China patent and adds to existing coverage in the U.S., Europe, and Japan. The company recently regained Nasdaq compliance after a 1-for-15 reverse split and faces a going concern warning with a cash runway ending this month. The patent strengthens the commercial moat for CyPath Lung, which has shown 92% sensitivity and 99% negative predictive value in trials. Watch for further commercialization updates and any capital raises given the tight cash position.
At the time of this announcement, BIAF was trading at $8.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $4.56 to $109.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.